Drug intelligence / Profile preview

S(c)TIL

Development stage: Unknown
Lead developer: Beijing Chineo Medical Technology
Modality: Cell Therapies, Gene Therapies

Overview

S(c)TIL is a gene-modified tumor-infiltrating lymphocyte (TIL) cell therapy. It is currently under clinical investigation for the treatment of gynecological malignancies and advanced malignant solid tumors. Developed by Beijing ChineoMedical Technology Co., Ltd, this therapy involves genetically modifying a patient's own tumor-infiltrating lymphocytes to enhance their ability to recognize and eliminate cancer cells, often administered in combination with PD-1 monoclonal antibodies.

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on S(c)TIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S(c)TIL.

Explore the full profile